Alzheimer’s disease is often difficult to diagnose in its early stages, with patients spending an average of 3.5 years navigating appointments, assessments, and referrals before receiving a diagnosis. This lengthy process can delay access to treatment, support services, and care planning at a time when early intervention may offer the greatest benefit.
To help address this challenge, Cx Precision Medicine has developed NeuroFirst Memory, an AI-powered blood test designed to support earlier identification of patients who may be at risk for Alzheimer’s-related dementia. The test is intended for use in primary care settings, helping physicians determine which patients may require further neurological evaluation while reducing unnecessary specialist referrals. By providing a faster and more accessible screening approach, the technology has the potential to streamline the diagnostic journey for both patients and healthcare providers.
The innovation reflects a broader shift toward using artificial intelligence and biomarker-based testing to improve the detection and management of neurodegenerative diseases. In addition to supporting earlier decision-making, the approach could help healthcare systems allocate resources more effectively and improve access to specialized care for those who need it most. Cx Precision Medicine is also exploring future applications in areas such as Parkinson’s disease and Alzheimer’s subtype testing.
Want to learn more? Read the full article on StartUp Health to learn how Cx Precision Medicine is using AI and blood-based diagnostics to transform Alzheimer’s detection, reduce diagnostic delays, and improve patient care.
